Founder, Chairman of the Board
Marty Tenenbaum, PhD
Founder, Chairman of the BoardMarty Tenenbaum is a renowned computer scientist, Internet entrepreneur and cancer survivor. He founded Cancer Commons and CollabRx (NASD: CRLX) to help each cancer patient obtain the best possible outcome. He is an Internet commerce pioneer and visionary, having founded EIT (1990) and CommerceNet (1994) to accelerate business use of the Internet, and later, was an officer and director of Commerce One, Webify Solutions (sold to IBM in 2006), and Medstory (sold to Microsoft in 2007). He currently serves on the boards of Efficient Finance, Patients Like Me, and the Public Library of Science (PLoS). Dr. Tenenbaum is a fellow and former board member of the Association for the Advancement of Artificial Intelligence (AAAI), and a former consulting professor of Computer Science at Stanford. He holds B.S. and M.S. degrees in Electrical Engineering and Computer Science from MIT, and a Ph.D. from Stanford.
Erika Vial Monteverdi
Executive DirectorSince 2016, Erika has played a central role at Cancer Commons, one of Silicon Valley’s only nonprofits focused on serving cancer patients globally through aligning incentives around the patient to produce better outcomes. As Executive Director, Erika is responsible for overseeing the growth of Cancer Commons and operations. Today, Cancer Commons is one of the leading cancer knowledge networks. The network brings together the world’s top cancer experts, advisors, pharma, oncologists, and super-patient groups, all focused on delivering the best treatment option to each person with cancer, at scale globally. Before joining Cancer Commons, Erika took time to start a family here in the Bay Area after working abroad in Europe as a strategic management consultant in the Strategic Information Technology Practice in AT Kearney. She then moved into a leadership role with Wunderman, a global digital agency and CRM company, headquartered in New York with 200 offices in 70 markets. Erika earned her bachelor’s degree from the University of California, San Diego, where she double majored in Political Science and Economics and received her International MBA from SDA Bocconi in Milan, Italy, one of the most prestigious business schools in the world. Erika is fluent in three languages, a mother of three, and is committed to helping the lives of others while making an impact on the organizations she serves.
Cancer Commons Nurse Navigator
Leslie Jared, RN, MSN
Cancer Commons Nurse NavigatorLeslie Jared, RN, MSN, is a registered nurse by training with extensive experience in clinical oncology and cancer research. She received her degrees in Nursing from Purdue University (Baccalaureate) and Vanderbilt University (Master of Science). Prior to joining Cancer Commons she was a Senior Clinical Operations Manager at Clinipace Clinical Research, a Contract Research Organization (CRO), where she managed all aspects of clinical operations of Phase I and II clinical trials. Additionally, she has several years’ experience in project management at other CROs. Prior to becoming involved in clinical research, she was an intensive care nurse at a major teaching hospital. As a 12-year survivor of ovarian cancer, she is passionate about helping others navigate the complex medical system to find the best treatment options available.
Cancer Commons Scientist
Kalpana Kannan, PhD
Cancer Commons ScientistKalpana Kannan, PhD, is a molecular biologist by training with extensive interest in cancer genomics and cancer signaling pathways. She received her PhD in Biochemistry from Texas A&M University, where she defined the components of the plant telomerase ribonucleoprotein complex. As a postdoctoral associate at Baylor College of Medicine, she was interested in understanding the changes in the transcriptome in patient tumors. This led to the identification of novel gene fusions in high-grade serous ovarian cancer that mainly target the PI3K/AKT signaling pathway. Kalpana also identified chimeric RNAs in prostate cancers that are promising non-invasive urine biomarkers. At the Helen Diller Cancer Center at UCSF, she continued to focus on cancer research. She developed CRISPR/Cas9 tools for genome-wide screens in breast cancer cell line models as well as studied the drug sensitivity of certain mutations found in metastatic breast cancer patients. Before joining Cancer Commons, Kalpana worked briefly at a start-up to develop a clinical-grade next generation sequencing platform for genetic cancer testing.
Editor in Chief
George Lundberg, MD
Editor in ChiefA 1995 “pioneer” of the medical Internet, Dr. Lundberg was born in Florida in 1933, grew up in lower Alabama, and holds earned and honorary degrees from North Park College; Baylor University; the University of Alabama (Birmingham and Tuscaloosa); the State University of New York, Syracuse; Thomas Jefferson University; and the Medical College of Ohio.
Dr. Lundberg received his MD in 1957 and has split the ensuing 62 work years across 4 key domains:
First Quarter: government service; U.S. Army Medical Corps, Vietnam Era, LTC, and Los Angeles County (Laboratory Director).
Second Quarter: full time academia; USC (Professor of Pathology) and UC Davis (Professor and Chair of Pathology).
Third Quarter: not-for-profit publishing (Editor in Chief JAMA and VP for all scientific publishing AMA)
Fourth Quarter: for-profit entrepreneurialism (Medscape, WebMD, MedPage Today, Everyday Health, CollabRx, Self Care Catalysts, PotentiaMetrics, Cureus) and not for profit (Cancer Commons, Harvard, Stanford, Northwestern,The Lundberg Institute).
Dr. Lundberg has worked in tropical medicine and forensic medicine in multiple countries. He is past president of the American Society for Clinical Pathology. A frequent lecturer and webcasting guest and host and a member of the National Academy of Medicine, in 2000, The Industry Standard dubbed Dr. Lundberg “Online Healthcare’s Medicine Man.”
Development Officer, Patient Concierge
Development Officer, Patient ConciergeAs Cancer Commons’ patient concierge, Sandy serves as a personal liaison to major donors, their colleagues, families and friends navigating their cancer journey via Ask Cancer Commons in search of relevant trials, treatment options, and expert insights and rationales to share with their oncological team for the best possible outcome. As Cancer Commons’ development officer, Sandy collaborates with our leadership and major donors to thoughtfully grow and strengthen Cancer Commons’ network of support. Sandy also works as a consulting development officer for the Hide & Seek Foundation for Lysosomal Research, raising funds in support of collaborative, cutting-edge medical research, and knows well how intellectual exploration and collaboration can lead to magnificent contributions. Prior to joining the Cancer Commons team, Sandy managed a $5M round one capital investor fundraising program at CollabRx, Inc., developing a prospective investor list and working hand-in-hand with CollabRx Founder Marty Tenenbaum to cultivate prospective investors. Sandy has a M.A. from the University of Oregon School of Journalism and Communication.
Lead Scientist, Pancreas Cancer
Lola Rahib, PhD
Lead Scientist, Pancreas CancerLola Rahib earned her PhD at UCLA in biomedical engineering and has worked for several biotechnology start-up companies in the Los Angeles area. More recently she was at the Pancreatic Cancer Action Network where she led scientific research and initiatives including a molecular profiling program, a patient registry, and an early detection initiative. In addition, she has authored many publications that have contributed to the field of pancreas cancer, including the most cited paper of 2014 in the journal Cancer Research. The study projected cancer incidences and deaths to 2030, predicting that pancreatic cancer would move from the fourth to the second-leading cause of cancer-related death in the United States by 2030.
Emma Shtivelman, PhD
Chief ScientistEmma Shtivelman is a molecular and cell biologist with extensive experience in cancer biology. She has in-depth understanding of cancer signal transduction and metabolism, cancer models in vitro and in vivo, target and drug discovery and validation, assay development, and preclinical research. She has technical expertise in numerous modern methodologies employed to understand the molecular basis of human malignancies and advance preclinical and clinical research. Emma received her PhD in molecular biology from the Weizmann Institute of Science where she identified the fused transcript between two cellular genes, BCR and ABL in chronic myelogenous leukemia (CML), the first demonstration of an oncogenic gene product derived from a chromosomal translocation. As a postdoctoral fellow at the University of California, San Francisco (UCSF), she characterized the molecular consequences of chromosomal translocations in Burkitt lymphoma and identified gene products relevant to the pathogenesis of neuroblastoma. She worked at Systemix on establishing a novel SCID-hu metastasis model to enable the in vivo analysis of human tumor metastasis. She continued her research activity at the UCSF Cancer Center analyzing deregulation of signal transduction pathways in human cancer and the molecular underpinnings of metastatic progression. Before joining Cancer Commons, Emma worked at BioNovo, Inc., researching new drugs that selectively disrupt metabolism of breast and pancreatic cancers by targeting their metabolic preferences.
Science WriterAt Cancer Commons, Sarah Stanley prepares actionable, reader-friendly content for people dealing with cancer. She has also written for Stanford Medicine, PLOS, the University of Washington, Discover magazine, Popular Science, the American Geophysical Union, the Marine Biological Laboratory in Woods Hole, Massachusetts, and the European Molecular Biology Laboratory in Heidelberg, Germany. Sarah studied microbiology and at the University of California, Santa Barbara.
Executive AdministratorSae graduated from Keio University in 1997 and has since been leveraging her multi-lingual/cultural skills in support of diplomats (Brunei Embassy Japan) and C-Level Management (Malaysia & USA) in her EA career. A breast cancer survivor, Sae feels privileged and humbled to serve meaningfully towards achieving humanitarian objectives as part of the Cancer Commons team.
Director of Administration, Executive Assistant to the Founder & Chairman
Director of Administration, Executive Assistant to the Founder & ChairmanAs Director of Administration and Executive Assistant to Marty Tenenbaum, Masako works behind the scenes, taking care of critical logistics so that Marty can focus on the bigger vision of Cancer Commons and make it a reality. Prior to joining Cancer Commons, Masako worked in a variety of sectors, including venture capital, real estate, academia, and technology. With 10+ years of experience supporting C-level executives, she aspires to apply all her knowledge and assist the team to achieve the best resolutions. As a non-smoker lung cancer survivor, she is committed to increasing awareness of the stigma surrounding this particular form of cancer. Masako, a native of Japan, has a B.A. in music and teaches piano and voice. She also performs at local venues including hospitals and care facilities. She recently directed a program to benefit Cancer Commons and performed music by George Gershwin, who is believed to have succumbed to glioblastoma.